Table 2 Associations between circulating biomarkers of inflammation and overall mortality over a 10-year follow-up, among all eligible stage II–III CRC cases (n = 306) and among those with CRP < 10 mg/L (n = 248).

From: Association between post-treatment circulating biomarkers of inflammation and survival among stage II–III colorectal cancer patients

Markers

All participants (n = 306)

CRP ≤ 10 mg/L (n = 248)

No. of deaths/total

Model 1a

Model 2b

No. of deaths/total

Model 1a

Model 2b

HR

95% CI

Ptrend

HR

95% CI

Ptrend

HR

95% CI

Ptrend

HR

95% CI

Ptrend

CRP

  ln(CRP)c

 

1.28

1.07–1.52

 

1.32

1.10–1.59

  

1.06

0.82–1.38

 

1.02

0.77–1.35

 

  Q1

22/78

1.00

Ref.

0.08

1.00

Ref.

0.07

22/78

1.00

Ref.

0.91

1.00

Ref.

0.67

  Q2

13/76

0.47

0.24–0.94

 

0.51

0.25–1.02

 

13/76

0.46

0.23–0.92

 

0.45

0.22–0.93

 

  Q3

28/76

1.05

0.59–1.85

 

1.07

0.58–1.95

 

28/76

1.03

0.58–1.83

 

0.91

0.49–1.69

 

  Q4

31/76

1.29

0.74–2.27

 

1.38

0.76–2.52

 

4/18

0.58

0.2–1.71

 

0.58

0.2–1.71

 

IL-6

  ln(IL-6)c

 

2.56

1.95–3.36

 

2.72

2.07–3.56

  

2.88

2.01–4.13

 

3.01

2.10–4.32

 

  Q1

8/78

1.00

Ref.

<0.0001

1.00

Ref.

<0.0001

6/75

1.00

Ref.

<0.0001

1.00

Ref.

<0.0001

  Q2

17/76

1.96

0.84–4.58

 

2.73

1.14–6.50

 

15/72

2.39

0.92–6.20

 

3.28

1.23–8.71

 

  Q3

29/76

3.35

1.50–7.47

 

4.57

1.99–10.46

 

27/65

5.38

2.18–13.26

 

6.95

2.73–17.69

 

  Q4

40/76

5.51

2.51–12.07

 

7.87

3.47–17.82

 

19/36

6.74

2.59–17.53

 

9.50

3.54–25.45

 

MCP-1

  ln(MCP-1)c

 

1.89

1.13–3.17

 

1.97

1.18–3.28

  

1.60

0.75–3.4

 

1.65

0.78–3.52

 

  Q1

18/78

1.00

Ref.

0.09

1.00

Ref.

0.06

14/71

1.00

Ref.

0.25

1.00

Ref.

0.26

  Q2

17/76

0.69

0.35–1.36

 

0.69

0.35–1.35

 

15/67

0.84

0.4–1.77

 

0.82

0.39–1.72

 

  Q3

29/76

1.28

0.70–2.36

 

1.33

0.72–2.46

 

20/60

1.18

0.58–2.41

 

1.16

0.57–2.36

 

  Q4

30/76

1.38

0.74–2.57

 

1.45

0.78–2.72

 

18/50

1.38

0.65–2.93

 

1.37

0.64–2.93

 

Adiponectin

  ln(Adip)c

 

1.73

1.16–2.59

 

1.71

1.14–2.58

  

1.88

1.16–3.03

 

1.87

1.15–3.04

 

  Q1

14/78

1.00

Ref.

0.001

1.00

Ref.

0.001

10/61

1.00

Ref.

0.005

1.00

Ref.

0.004

  Q2

17/76

1.20

0.59–2.44

 

1.20

0.58–2.45

 

10/60

0.87

0.36–2.11

 

0.82

0.34–2.01

 

  Q3

29/76

1.98

1.03–3.79

 

2.02

1.04–3.91

 

24/65

2.14

1.01–4.52

 

2.23

1.04–4.79

 

  Q4

34/76

2.55

1.35–4.82

 

2.56

1.34–4.9

 

23/62

2.26

1.06–4.83

 

2.32

1.07–5.03

 

Leptin

  ln(Leptin)c

 

0.86

0.72–1.02

 

0.85

0.70–1.03

  

0.98

0.79–1.21

 

0.93

0.73–1.19

 

  Q1

27/78

1.00

Ref.

0.15

1.00

Ref.

0.16

17/66

1.00

Ref.

0.67

1.00

Ref.

0.39

  Q2

23/76

1.01

0.57–1.77

 

1.06

0.59–1.89

 

18/67

1.24

0.63–2.44

 

1.28

0.64–2.54

 

  Q3

27/76

0.93

0.54–1.59

 

0.95

0.53–1.68

 

20/59

1.22

0.63–2.34

 

1.15

0.57–2.3

 

  Q4

17/76

0.62

0.34–1.15

 

0.59

0.29–1.17

 

12/56

0.81

0.39–1.72

 

0.64

0.27–1.51

 
  1. CRC colorectal cancer, CRP C-reactive protein, IL-6 interleukin-6, MCP-1 monocyte chemoattractive protein-1, HR hazard ratio, CI confidence interval.
  2. aModel 1 was stratified by stage at diagnosis and adjusted for age at blood draw, sex, smoking status at baseline, regular use of non-steroidal anti-inflammatory drugs (NSAIDs) at baseline, plasma storage time and years between diagnosis and blood draw.
  3. bModel 2 was stratified by stage at diagnosis and adjusted for all covariates in Model 1 plus pre-diagnostic body mass index.
  4. cHRs for overall mortality per unit increase in log-transformed concentrations of each biomarker; tests for trend (Ptrend) were conducted by including the categorical variable (i.e. quartiles) in the model as an ordinal variable and calculating the Wald statistic.
Back to article page